問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林恭平

Recruiting

List

24Cases

2021-07-14 - 2027-04-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-04-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-07-01 - 2031-10-30

Phase III

Active
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    Remibrutinib

Participate Sites
4Sites

Recruiting4Sites

2023-12-15 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-04-01 - 2026-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2025-12-31

Phase III

Completed
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Condition/Disease

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Test Drug

    ENSPRYNG 120mg for SC Injection

Participate Sites
4Sites

Recruiting4Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2024-07-01 - 2026-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-11-01 - 2028-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-02-27 - 2023-12-31

Phase III

A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)

  • Condition/Disease

    Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM)

  • Test Drug

    Tafamidis (PF-06291826)

Participate Sites
2Sites

Recruiting2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB